Dream Team of Docs Will Study Cancer Switch

Researchers at MD Anderson Cancer Center will be part of a so-called “Dream Team” that will use new grant money to find ways to beat a key switch in the development of an array of cancers. Capella Tucker reports.


To embed this piece of audio in your site, please use this code:

<iframe src="" style="height: 115px; width: 100%;"></iframe>

The team also includes cancer researchers at Harvard Medical School, Sloan Kettering Cancer Center in New York and medical schools at Columbia and Vanderbilt. Researchers will get 15-million dollars over the next three years from Stand Up To Cancer, an entertainment industry-sponsored telethon that aired last fall. The MD Anderson Cancer Center’s Dr. Gordon Mills is part of the “Dream Team” and says his group will look for ways to treat a mutated molecular pathway that shows-up in many cancers.

“It is abnormal is more types of cancers and in more patients than any other pathway in cancer and we now have drugs that we believe can target these abnormalities, correct them and make a great impact for patients.”
Mills says his team will look for ways to challenge the abnormal processes in the molecular pathway and find out which drugs treat the problem in the most efficient and effective way.

“The whole team is on the field. No one is left on the bench. We’re going to do what we can. We’re going to put all of our efforts into this. And this is really a culmination for many of us of years of work to get to the point where we really can change outcomes for patients and the team is very excited about moving forward.”

The teams will first look at cancers in women, including breast and ovarian cancers, as part of the grant.  

Subscribe to Today in Houston

Fill out the form below to subscribe our new daily editorial newsletter from the HPM Newsroom.

* required